Nintedanib slows progression for broad range of scarring lung diseases
Nintedanib, a medication approved for the treatment of idiopathic pulmonary fibrosis, slows the decline in lung function among patients with a broad range of scarring lung diseases. The findings, published in the New England ...
Sep 30, 2019
0
34